• 1
    Yamaguchi O, Nishizawa O, Takeda M et al. Clinical Guideline for Overactive Bladder . Tokyo: Blackwell Publishing, 2008.
  • 2
    Ubee SS, Manikandan R, Singh G. Medical management of overactive bladder. Indian J Urol 2010; 26: 2708.
  • 3
    Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195201.
  • 4
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 6927.
  • 5
    Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: 948.
  • 6
    Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005; 96: 84852.
  • 7
    Schmid DM, Sauermann P, Werner M et al. 140. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176: 17785.
  • 8
    Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 22316.
  • 9
    Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180: 21722.
  • 10
    Cohen BL, Barboglio P, Rodriguez D, Gousse AE. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009; 28: 2058.
  • 11
    Chancellor MB, Fowler CJ, Apostolidis A et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5: 31928.
  • 12
    Watanabe T, Saito M, Hirakawa S, Miyagawa I. The effect of botulinum toxin injection into the bladder for overactive bladder: two case. Jpn J Urol 2005; 96: 5114. (In Japanese.)
  • 13
    Okamura K, Nojiri Y, Ameda K et al. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. Int J Urol 2011; 18: 4837.
  • 14
    Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 2006; 68: 31823.
  • 15
    Gotoh M, Homma Y, Funahashi Y, Matsukawa Y, Kato M. Psychometric validation of the Japanese version of the International Consultation on Incontinence Questionnaire-Short Form. Int J Urol 2009; 16: 3036.
  • 16
    Okamura K, Nojiri Y, Osuga Y, Tange C. Psychometric analysis of international prostate symptom score for female lower urinary tract symptoms. Urology 2009; 73: 1199202.
  • 17
    Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009; 181: 260815.
  • 18
    Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184: 241622.
  • 19
    Sahai A, Downson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009; 103: 150915.
  • 20
    Flynn MK, Webster GD, Amundsen CL. The effect of botulinum A toxin on patients with severe urge urinary incontinence. J Urol 2004; 172: 231620.
  • 21
    Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010; 58: 91926.
  • 22
    van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 44052.
  • 23
    Chen YC, Kuo HC. Difficult urination does not affect the successful outcome after 100U onabotulinumtoxinA intravesical injection in patients with idiopathic detrusor overactivity. LUTS 2012; 4: 2934.